Response to Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128-2136.

Roselle A HerringFariba Shojaee-MoradieRobert GaresseMary StevenageNicola JacksonBarbara A FieldingAgampodi MendisSigurd JohnsenA Margot UmplebyMelanie DaviesDavid L Russell-Jones

Published in: Diabetes care (2021)

Keyphrases

liver failure
type diabetes
respiratory failure
drug induced
aortic dissection
glycemic control
metabolic syndrome
intensive care unit
adipose tissue
insulin resistance